1 "parallel study of two doses of intravenous MDL73" modia (modia): 1992
2 "in cancer patientstreated with cisplatin" 97-102, 1994
3 "and metoclopramideplus dexamethasone in patients receiving cisplatin" Cirrincione C 108-14, 1989
4 "a potent and selective antagonist at 5-HT3 receptors" 87-93, 1993
5 "Urinary serotonin metabolite excretion during cisplatin chemotherapy" 72 : 2239-41, 1993
6 "The impact of cytotoxic chemotherapy--perspectives from patients" 1-8, 1992
7 "Potent 5-HT3 antagonists incorporating anovel bridged pseudopelletierine ring system" 16 : 187-9, 1989
8 "Pharmacokineticsof dolasetron following single- and multiple- doseintravenous administration to normal male subjects" 16 : 177-189, 1995
9 "On the receiving end--patient perception of theside-effects of cancer chemotherapy" 19 : 203-8, 1983
10 "Efficacy of intravenous granisetron to control nauseaand vomiting during multiple cycles of cisplatin-based chemotherapy" 16 : 87-93, 1998
1 "parallel study of two doses of intravenous MDL73" modia (modia): 1992
2 "in cancer patientstreated with cisplatin" 97-102, 1994
3 "and metoclopramideplus dexamethasone in patients receiving cisplatin" Cirrincione C 108-14, 1989
4 "a potent and selective antagonist at 5-HT3 receptors" 87-93, 1993
5 "Urinary serotonin metabolite excretion during cisplatin chemotherapy" 72 : 2239-41, 1993
6 "The impact of cytotoxic chemotherapy--perspectives from patients" 1-8, 1992
7 "Potent 5-HT3 antagonists incorporating anovel bridged pseudopelletierine ring system" 16 : 187-9, 1989
8 "Pharmacokineticsof dolasetron following single- and multiple- doseintravenous administration to normal male subjects" 16 : 177-189, 1995
9 "On the receiving end--patient perception of theside-effects of cancer chemotherapy" 19 : 203-8, 1983
10 "Efficacy of intravenous granisetron to control nauseaand vomiting during multiple cycles of cisplatin-based chemotherapy" 16 : 87-93, 1998
11 "Double-blind, randomized comparison of the antiemeticefficacy of intravenous dolasetron mesylate and intravenousondansetron in the prevention of acute cisplatin-inducedemesis in patients with cancer" Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group 14 : 2242-2249, 1996
12 "Dose-ranging evaluation of the serotonin antagonistdolasetron mesylate in patients receiving high-dosecisplatin" 12 : 1045-9, 1994
13 "Dose-ranging evaluation of the antiemeticefficacy of intravenous dolasetron in patients receiving chemotherapywith doxorubicin or cyclophosphamide" 4 : 141-146, 1996
14 "Dolasetron mesylate" 18 : 506-9, 1993
15 "Disposition following single- doseintravenous administration to normal male subjects" 693-701, 1992
16 "Comparative review of 5-HT3 receptor antagonistsin the treatment of acute chemotherapy-induced nausea andvomiting" 18 : 163-173, 2000
17 "Closing the gap in prophylactic antiemetictherapy patient factors in calculating the emetogenic potentialof chemotherapy" 3 : 113-119, 1999
18 "Characterization of the novel 5-HT3 antagonists MDL73147EF and MDL 74156 in NG108-15neuroblastoma x glioma cells" 9-13, 1992
19 "A randomized comparison of antiemetic effect of ondansetronversus MDL" 378-389, 1992
20 "A double-blind randomized study comparing intramuscular(i.m.) granisetron with i.m. granisetron plus dexamethasone inthe prevention of delayed emesis induced by cisplatin" TheItalian Multicenter Study Group 10 : 465-470, 1999
21 "5-HT3 receptor antagonists for theprevention of chemotherapy-induced nausea and vomiting" 55 : 173-189, 1998